A Phase I Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects
Latest Information Update: 06 Mar 2024
Price :
$35 *
At a glance
- Drugs HRS 5685 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors RetroLead (Shanghai) BioPharma
- 20 Apr 2022 New trial record